This page is updated frequently with new Cytokine-related patent applications.
| Il-17a/f heterologous polypeptides and therapeutic uses thereof|
The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17f designated herein as interleukin 17a/f (il-17a/f). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
| Engineered antibody-interferon mutant fusion molecules|
The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (taa) antibody (ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell.
| Method for inducing a trif-bias|
Compositions comprising a selected aminoalkyl glusoaminide 4-phosphate (agp) crx-547 to induce a trif-biased response in a human system, which results in reduced levels of myd88-dependent cytokines relative to the myd88-dependent cytokines induced by its diastereomer agp crx-527.. .
Glaxosmithkline Biologicals S.a.
| Targeted mutant alpha-helical bundle cytokines|
This disclosure relates to a modified α-helical bundle cytokine, with reduced activity via an α-helical bundle cytokine receptor, wherein the α-helical bundle cytokine is specifically delivered to target cells. Preferably, the α-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells.
|Enhancing serological assays via fusion proteins|
A serological assay with an improved linear range of detection is disclosed using a fusion protein system, such as an anti-cytokine/cytokine fusion protein (acyf) system, for evaluating immune responses. Also disclosed are related compositions, fusion proteins, expression vectors, monoclonal antibodies, and kits for practicing the assay method of the present invention..
|Transdiscal administration of specific inhibitors of pro-inflammatory cytokines|
The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.. .
Depuy Synthes Products, Llc
|Methods for catheter-based renal neuromodulation|
Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
|Methods for therapeutic renal neuromodulation|
Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
|Methods for diagnosing celiac disease using circulating cytokines/chemokines|
Provided herein are compositions, kits, and methods for measuring circulating cytokines and chemokines in a subject that has or is suspected of having celiac disease.. .
|Methods for diagnosis and prognosis of inflammatory bowel disease using cytokine profiles|
The present invention relates to the field of inflammatory bowel disease. More specifically, the present invention relates to the use of cytokines to detect, diagnose, and assess inflammatory bowel disease.
Oklahoma Medical Research Foundation
Tetrameric cytokines with improved biological activity
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-mab dnl complex comprises an igg antibody attached to two ad (anchor domain) moieties and four cytokines, each attached to a ddd (docking and dimerization domain) moiety.
Ibc Pharmaceuticals, Inc.
Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same
Provided herein are immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same.. .
Ifm Therapeutics, Inc
Cancer therapy using beta glucan and antibodies
The present invention relates to methods of using neutral soluble glucan and monoclonal antibodies for antitumor therapy. Neutral soluble beta (1,3; 1,6) glucan (nsg) enhances the tumoricidal activity of the innate immune system by binding to the c3 complement protein receptor cr3.
University Of Louisville Research Foundation, Inc.
Immune hepatotoxicity screening method using hepatocytes derived from human stem cells
The present invention relates to an immune hepatotoxicity screening method using hepatocytes derived from human stem cells. After hepatocytes differentiated from human stem cells and human hepatocytes are treated with ethanol, ccl4, and acetaminophen to induce immune hepatotoxicity, a hepatocellular immunotoxic material assay system is constructed in order to verify cytokines, chemokines, and lipid mediators, which are mediators secreted from the hepatocytes, and an immunotoxic material can be confirmed in the cells having the induced hepatotoxicity by using the system.
Korea Advanced Institute Of Science And Technology
Methods of developing selective peptide antagonists
Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families.
Peptide having anti-inflammatory, osteogenic and hair growth promoting activities, and use of same
Provided is a peptide, which has an anti-inflammatory activity and an activity for promoting osteogenic differentiation, formed from the amino acid sequence selected from the group comprising the amino acid sequences of seq id no: 1, seq id no: 2, and seq id no: 3. And provided is a peptide, which has a hair growth promoting activity, formed from the amino acid sequence selected from the group comprising the amino acid sequences of seq id no: 1 and seq id no: 2.
Caregen Co., Ltd.
Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation
A composition for human and animal use as a therapy for the treatment of tumors, acquired immunodeficiency syndrome and leukemias is described. The composition, for human and animal use as an antitumor agent has a strain of bacteria lactobacillus reuteri lre 03 dsm 23879 which is able to strongly stimulate the production of pro-inflammatory cytokines (th1) interferon inf-gamma, the cytokines exhibiting a marked antitumor activity, and/or a strain of bacteria lactobacillus salivarius ls06 dsm 26037 which is able to strongly stimulate the production of dendritic cells, the dendritic cells also exhibiting a marked antitumor activity..
Host cell modification with artificial endosymbionts
The present invention is directed generally to host cells with artificial endosymbionts, wherein the artificial endosymbiont and the host cell communicate with each other to alter a phenotype of the host cell. In some embodiments, the communication comprises the secretion of a polypeptide from the artificial endosymbiont into the host cell.
Bell Biosystems, Inc.
Method for preparing and using cell ghost with active factors as synergist of lymphocyte in vitro culture
Provided is a method for preparing and using cell ghosts with active factors as a synergist of a lymphocyte in vitro culture. The method for preparing cell ghosts comprises: washing a cell to obtain a washed cell; and cleaving the washed cell to obtain cell ghosts, wherein the cell has cytokines capable of promoting the proliferation and differentiation of lymphocytes on their surface..
Compositions and methods for treating cytokine-related disorders
Compositions and methods for treating a cytokine release syndrome such as chimeric antigen receptor t-cell cytokine release syndrome or hemophagocytic lymphohistiocytosis are provided.. .
Trustees Of The University Of Pennsylvania
Vhnar anti-cytokine domains
The present invention concerns therapeutic compositions containing proteins that are the variable regions of ignar immunoglobulins, denominated vnar, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.. .
Laboratorios Silanes S.a. De C.v.
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
Wherein a is ch or n, p is in a range from 1 to 50, r″ is a bond or -alkylene-o—, r′ is alkylene that is optionally interrupted or terminated with one or more amide or ether groups, and e is an amine- or thiol-reactive group. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed.
Implantable device for automatic delivery of medication for allergic reactions
Apparatus, implanted subcutaneously or in muscle, fat, joint spaces, or body cavities of any type, detects and responds to an allergic and/or anaphylactic reaction. Detection is carried out by monitoring the levels of biomarker molecules that indicate the occurrence of an allergic and/or anaphylactic reaction, such as: histamine, leukotrienes, prostaglandins, cytokines, tryptase, fc-ε-ri complexes, anaphylatoxin c3a, chymase, carboxypeptidase a, platelet-activating factor8, other mast cell degranulation byproducts, or other basophil activation compounds.
Compositions and methods for inhibiting pro-inflammatory cytokine gene expression
θ-defensins, non-human macrocyclic peptides, have been found to reduce expression of genes encoding for various pro-inflammatory peptides (such as cytokines and chemokines) in a highly selective manner. Methods for treating inflammatory conditions utilizing a θ-defensin and/or a θ-defensin analog, methods for modifying (e.g.
The Regents Of The University Of California
Novel cell-derived composition
The invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties termed amnion-derived cellular cytokine solution-b (accs-b).
Noveome Biotherapeutics, Inc.
Method of treating t cell mediated disorders
A method of treating a t-cell mediated disorders in a tissue includes administering to the tissue of the subject a therapeutically effective amount of a complement antagonist that substantially reduces t-cell differentiation or t-cell inflammatory cytokine generation.. .
Case Western Reserve University
Macrophage inhibitory cytokine-1 (mic-1) as a prognostic marker in chronic kidney disease
The present invention relates to methods of prognosing the survival of a diseased subject, particularly a subject with chronic kidney disease (ckd), as well as selecting an end-stage renal disease subject for a kidney transplant. The methods involve detecting an elevated amount of macrophage inhibitory cytoking-1 (mid-1) in a test body sample from the diseased subject.
St Vincent's Hospital Sydney Limited
Methods and multi-vessel renal neuromodulation
Methods and apparatus are provided for multi-vessel neuromodulation, e.g., via a pulsed electric field. Such multi-vessel neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
Combination therapy for the treatment of autoimmune diseases
The present invention pertains to compounds and their combination for use in the prevention or therapy of a subject suffering from an autoimmune disease such as diabetes type 1. Provided are antagonists of t-cells that are used in combination with antagonists of the cytokine cxcl10, sequentially or concomitantly, in a subject suffering from an autoimmune disease, in particular diabetes type 1..
Fraunhofer-gesellschaft Zur Förderung Der Angewandten Forschung E.v.
The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same.. .
The University Of North Carolina At Chapel Hill
Defined composition gene modified t-cell products
Aspects of the invention described herein, concern approaches to make genetically modified t-cells comprising a chimeric antigen receptor for human therapy. In some alternatives, the methods utilize a selection and/or isolation of cd4+ and/or cd8+ t-cells from a mixed t-cell population, such as, peripheral blood or apheresis derived mononuclear cells.
Seattle Children's Hospital (dba Seattle Children's Research Institute)
Production of cytotoxic antibody-toxin fusion in eukaryotic algae
Methods and compositions are disclosed to engineer chloroplast comprising heterologous genes encoding target binding domain fused to a eukaryotic toxin and produced within a subcellular organelle, such as a chloroplast. The present disclosure demonstrates that when chloroplasts are used, toxins normally refractive to production in eukaryotic cells may be used to produce recombinant fusion proteins with binding domains that are soluble, properly folded and post-translationally modified, where the multifunctional activity of the fusion protein is intact.
Methods and pulsed electric field neuromodulation via an intra-to-extravascular approach
Methods and apparatus are provided for pulsed electric field neuromodulation via an intra-to-extravascular approach, e.g., to effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, changes in cytokine upregulation and other conditions in target neural fibers. In some embodiments, the itev pef system comprises an intravascular catheter having one or more electrodes configured for intra-to-extravascular placement across a wall of patient's vessel into proximity with target neural fibers.
Medtronic Ardian Luxembourg S.a.r.i.
Engineered cytokine- and chemokine-expressing candida albicans strains and methods of use
Recombinant nucleic acid constructs for expression of heterologous cytokines or chemokines in c. Albicans, and genetically modified c.
Carnegie Mellon University